

**CURRICULUM VITAE
PROF. ANDREA GIUSTINA**

Andrea Giustina

Born in Milano 24/01/1962

Position Full Professor of Endocrinology and Metabolism

Institution and Location University Vita-Salute San Raffaele, Milano, Italy

July 1986	Medical Degree
May 1991	Assistant Professor in Internal Medicine, University of Brescia
1991/1994	Associate Professor of Endocrinology, University of Wisconsin – Milwaukee (USA)
July 1992	Specialist in Internal Medicine
October 1997	Specialist in Endocrinology and Metabolism
January 1998	Member Editorial Board Journal of Clinical Endocrinology and Metabolism
February 1998	Member Publication Committee Italian Society of Endocrinology
April 1998	Member Editorial Board of Pituitary
July 1998	Member Scientific Committee Italian Society of Diabetology
November 1998	Member Editorial Board of Clinical Endocrinology
January 2000	Coordinator, Endocrine unit “C. Poma” Hospital of Mantova
November 2001	Associate Professor of Internal Medicine, University of Brescia
January 2003	Member Scientific Committee of the Italian Society of Endocrinology
June 2003	Chairman of the Clinical Initiatives Committee Of the Pituitary Society
January 2004	Reviewing Editor Journal of Endocrinological Investigation

June 2005	Editor of “Pituitary”.
September 2005	Full Professor in Internal Medicine
September 2006	Member “Journal Managing Subcommittee” The Endocrine Society
October 2007	Appointed Full Professor of Internal Medicine University of Brescia
October 2007	Head, Endocrine Service Montichiari Hospital
June 2008	Council member, PhD Program on “Biomedical Technologies in Clinical Medicine” La Sapienza University, Rome
February 2009	Director, Postdoctoral Program in Osteoporosis and Metabolic Bone diseases, University of Brescia
April 2009	Elected Member of the Executive Council, European Society of Endocrinology
October 2009	Appointed Member of the Nominations Committee, European Society of Endocrinology
March 2010	Nominated member of the Executive Council of the Joint Postgraduate School of Endocrinology (University of Varese, Milano and Brescia)
December 2010	Research Career Prize of Italian Society of Osteoporosis
February 2011	Editor-in-Chief Endocrine
March 2011	GIOSEG (Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group) President
April 2011	Chairman, Nomination Committee European Society of Endocrinology
June 2011	Elected, Board of Directors, Pituitary Society
June 2011	Member of POC 12th Pituitary Congress (Boston)
July 2011	Chairman of the “Committee of International Affairs” of Italian Society of Endocrinology
June 2012	Member of the Executive Committee of the International Society of Endocrinology
September 2012	Co-Chair Sixth Fellows Forum on Metabolic Bone

Diseases (Minneapolis)

October 2012	Full Professor in Endocrinology and Metabolism, University of Brescia
October 2012	Director Postgraduate School in Endocrinology and Metabolism, University of Brescia
November 2012	Scientific Director of the Research Center in Osteoporosis and bone metabolism (CROMO) University of Brescia
April 2013	Member, Clinical Committee European Society of Endocrinology
June 2013	Member of POC 13th Pituitary Congress (San Francisco)
August 2013	Head, Endocrine outpatient Clinic, Brescia Hospital
September 2013	Co-Chair Seventh Fellows Forum on Metabolic Bone Diseases (Baltimore)
January 2014	Principal Investigator LAUTI Italian Multicenter Study (Lanreotide up-titration in Acromegaly)
March 2015	Member of the jury CET Prize
June 2015	Member National Commission for Postgraduate Schools of the Italian Ministry of University (MIUR)
October 2015	Elected member of the Executive Council of Italian Society for Osteoporosis (SIOMMMS)
January 2016	Chairman Scientific Committee SIOMMMS
April 2016	Member POC ECE 2017
June 2016	President Pituitary Society
October 2016	Member, Steering Committee Chiasma International Study on Octreolin in Acromegaly
January 2017	Full Professor of Endocrinology, University Vita-Salute San Raffaele Milano
March 2017	Expert panel member audition CHMP EMA on glucocorticoid-induced osteoporosis
April 2017	Co-Chair 1 st International Conference on Controversies in Vitamin D (Pisa)

May 2017	President Elect European Society of Endocrinology
July 2017	Co-Chair Congress Committee Pituitary Society
August 2017	Expert member of HCPWP Committee European Medicines Agency (EMA)
October 2017	Member Scientific Advisory Board IGTF Foundation (Barcelona, Spain)
Ottobre 2017	Dionisios Ikkos Award and lecture Hellenic Society of Endocrinology Athens
November 2017	Member Scientific Advisory Board Lorenzini Foundation (Milano – New York)
October 2017	Chair and Plenary Speaker 1 st Pituitary Masterclass Lisbon
February 2018	Chair, Policy and Advocacy Committee European Society of Endocrinology
March 2018	Editorial board member COEMR
March 2018	Co-Chair Meeting ESE meets European Institutions (European Parliament, Brussels)
May 2018	Expert audition AIFA on unmet needs in the treatment of Hypoparathyroidism
May 2018	Chair European Congress of Endocrinology Barcelona
June 2018	Co-Chair 12 th Acromegaly Consensus Meeting (Prague)
July 2018	Co-Chair 7 th Clinical Update in Endocrinology and Metabolism (CUEM – Milano)
September 2018	Chair 2 nd International Conference on Vitamin D Monteriggioni
September 2018	Chair International GH-IGF_1 Congress Seattle
September 2018	Endocrine Grand Round UCSF San Francisco
September 2018	Lecture Annual Congress ESMO Monaco di Baviera

October 2018	Coordinator Scientific Committee National Congress SIOMMMS Rome
November 2018	Delegate of Chancellor CRUI International
December 2018	Prorector for Institutional and International Relations UniSR Milano
December 2018	Head Division of Endocrinology IRCCS San Raffaele Hospital Milano
December 2018	Lecture International Congress of Endocrinology Capetown
January 2019	Member of Academic Senate UniSR Milano
January 2019	Director Postgraduate School in Endocrinology and Metabolic Diseases UniSR Miano
February 2019	Member Italian Superior Health Council Rome'
March 2019	Meet the Professor Annual Congress Endocrine Society New Orleans
March 2019	Lecture ESE Potgraduate Course Bled
April 2019	Lecture ESE Postgradua Course Riga
Match 2019	President European Society of Endocrinologyù
July 2019	President Clinical update in Endocrinology and Metabolism San Raffaele
August 2019	PI ENDORSE Study on Endocrine determinants of renal function in Hypoparathyroidism
September 2019	President 3 rd International Conference on Vitamin D Gubbio (Italy)
September 2019	Lecture Annual Congress ESMO Barcellona
October 2019	Inaugural Lecture National SIOMMMS Congress Bologna Italy
November 2019	Co-Chair 13 th Consensus Conference on Acromegaly Fort Lauerdale Florida
December 2019	President of National DXA Teaching Courses Bologna Napoli Milano

January 2020	Member Working Group on Fractures and Frailty Italian Superior Health Council
February 2020	PI Pilot Phase I PTCOE Accreditation International Collaborative Project
March 2020	Member Committe for National Examination for Postgraduate Schools MUR Rome
April 2020	Coordinator Working Group for Safety of Inernational Students CRUI Rome
May 2020	PI Bone and Covid19 Project San Raffaele Milano
June 2020	Co-Chair Inaugural Session ENDOonline 2020
July 2020	Co-founder and President, IDEA (International vitaminD Expert Association)
August 2020	Member of the Board of Directors, European Hormone and Metabolism (Ho.Me) Foundation
September 2020	Co-chair 4th International Conference on Controversies in Vitamin D
October 2020	Lecture, Consensus Conference on Cushing's disease Pituitary Society
November 2020	Lecture, Global Expert Summit on Hypoparathyroidism
January 2021	Member Steering Committee ESE PARAT Project on Parathyroid diseases
February 2021	President, 9th Skeletal Endocrinology Meeting
February 2021	Opening Lecture, International Pituitary Congress on COVID-19 and the Pituitary
March 2021	Co-Chair Special COVID Session ENDO 2021
March 2021	President LOC (Local Organizing Committee) ECE Milano 2022
March 2021	President of the Jury of the Geoffrey Harris prize
March 2021	Member of the Jury for the European Hormone Medal

April 2021

Member of the CSS working group on: Evaluation of artificial intelligence system as support of diagnostic processes

April 2021

Member of the Supervising Board, ECAS Centers of Special Interests

LIST OF PUBLICATIONS

1. Giustina A, Candrina R, Cimino A, Romanelli G. Development of isolated ACTH deficiency in a man with type I diabetes mellitus. *J Endocrinol Invest*. 1988;11(5):375-377. doi:10.1007/BF03349058
2. Giustina A, Romanelli G, Cimino A, Brunori G. Low-dose acyclovir and acute renal failure. *Ann Intern Med*. 1988;108(2):312. doi:10.7326/0003-4819-108-2-312_1
3. Candrina R, Giustina A. Malattia di Addison e ipotiroidismo [Addison's disease and hypothyroidism]. *Recenti Prog Med*. 1988;79(10):397-399.
4. Candrina R, Giustina A. Development of type II autoimmune polyglandular syndrome in a patient with idiopathic thrombocytopenic purpura. *Isr J Med Sci*. 1988;24(1):57-58.
5. Manganoni AM, Giustina A, Zuccato F, et al. Trattamento della psoriasi eritrodermica con ciclosporina [Treatment of erythrodermic psoriasis with cyclosporin]. *G Ital Dermatol Venereol*. 1988;123(12):675-676
6. Romanelli G, Agabiti-Rosei E, Giustina A, et al. Bacteriological and clinical evaluation of cefotetan in the treatment of severe infections in hospitalized patients. *Drugs Exp Clin Res*. 1988;14(6):411-417..
7. Giustina A, Candrina R, Romanelli G. Growth hormone deficiency, rapidly reversible during glucocorticoid replacement, in a case of adrenocorticotrophin deficiency. *Neth J Med*. 1988;33(5-6):291-297.
8. Romanelli G, Giustina A, Agabiti-Rosei E, et al. Short-term effect of captopril and nifedipine on micro-albuminuria induced by exercise in hypertensive diabetic patients. *J Hypertens Suppl*. 1989;7(6):S312-S313. doi:10.1097/00004872-198900076-00152
9. Giustina A, Scalvini T, Cerudelli B, et al. Ipopituitarismo secondario ad aneurisma gigante carotido-oftalmico soprasellare. Normalizzazione della funzione ipofisaria dopo decompressione neurochirurgica dell'aneurisma [Hypopituitarism secondary to suprasellar giant carotido-ophthalmic aneurysm. Normalization of the hypophyseal function after neurosurgical depression of the aneurysm]. *Minerva Endocrinol*. 1989;14(4):255-258.
10. Giustina A, Romanelli G, Doga M, Pizzocolo G, Giustina G. Effects of intranasal calcitonin administration on pituitary GH response to hGHRH (1-29)NH₂ in normal adult subjects. *Clin Endocrinol (Oxf)*. 1989;30(6):699-704. doi:10.1111/j.1365-2265.1989.tb00276.x
11. Valentini U, Cimino A, Rotondi A, et al. Growth hormone response to thyrotropin releasing hormone and placebo in a group of insulin dependent diabetic patients. *J Endocrinol Invest*. 1989;12(9):643-646. doi:10.1007/BF03350025

12. Giustina A, Romanelli G, Candrina R, Giustina G. Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. *J Clin Endocrinol Metab.* 1989;68(1):120-124. doi:10.1210/jcem-68-1-120
13. Romanelli G, Giustina A, Cimino A, et al. Short term effect of captopril on microalbuminuria induced by exercise in normotensive diabetics. *BMJ.* 1989;298(6669):284-288. doi:10.1136/bmj.298.6669.284
14. Giustina A, Romanelli G, Bossoni S, et al. Effects of short-term glucocorticoid deprivation on growth hormone (GH) response to GH-releasing hormone in man. *Horm Metab Res.* 1989;21(12):693-694. doi:10.1055/s-2007-1009324
15. Giustina A, Romanelli G, Cravarezza P, Ravizzola G, Turano A. Pefloxacin in the treatment of acute severe infections in hospitalized patients. Clinical and bacteriological evaluation. *J Chemother.* 1989;1(4 Suppl):668-669.
16. Giustina A, Romanelli G, Cravarezza P, Ravizzola G, Turano A. Pefloxacin in the treatment of acute severe infections in hospitalized patients. Clinical and bacteriological evaluation. *J Chemother.* 1989;1(4 Suppl):668-669.
17. Giustina A, Macca C, Bossoni S, Romanelli G, Zuccato F. La calcitonina di salmone spray nasale nella terapia del morbo di Paget [Salmon calcitonin nasal spray in the treatment of Paget's disease]. *Recenti Prog Med.* 1989;80(11):599-602.
18. Giustina A, Cravarezza P, Romanelli G, Spandrio S, Zuccato F. Effect of age on beta-cell response to exogenous glucagon in man. *Horm Metab Res.* 1989;21(5):277-279. doi:10.1055/s-2007-1009212
19. Giustina A, Bossoni S, Cimino A, Pizzocolo G, Romanelli G, Wehrenberg WB. Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. *J Clin Endocrinol Metab.* 1990;71(6):1486-1490. doi:10.1210/jcem-71-6-1486
20. Romanelli G, Giustina A, Cravarezza P, et al. A single dose of aztreonam in the prevention of urinary tract infections in elderly catheterized patients. *J Chemother.* 1990;2(3):178-181. doi:10.1080/1120009x.1990.11739014
21. Giustina A, Bodini C, Bossoni S, et al. Effects of calcitonin on GH response to pyridostigmine in combination with hGHRH (1-29) NH₂ in normal adult subjects. *Clin Endocrinol (Oxf).* 1990;33(3):375-380. doi:10.1111/j.1365-2265.1990.tb00502.x
22. Giustina A, Ferrari C, Bodini C, et al. Effects of methimazole treatment on growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism. *Acta Endocrinol (Copenh).* 1990;123(6):613-618. doi:10.1530/acta.0.1230613
23. Giustina A, Girelli A, Doga M, et al. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. *J Clin Endocrinol Metab.* 1990;71(3):580-584. doi:10.1210/jcem-71-3-580
24. Romanelli G, Giustina A, Bossoni S, et al. Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy. *Diabetes.* 1990;39(11):1333-1338. doi:10.2337/diab.39.11.1333
25. Giustina A, Romanelli G, Bossoni S, et al. Effetto della somministrazione acuta di nifedipina sulla microalbuminuria da sforzo in pazienti diabetici di tipo 1 normotesi [Effects of acute administration of nifedipine on exercise-induced microalbuminuria in normotensive patients with type 1 diabetes]. *Ann Ital Med Int.* 1990;5(4 Pt 1):353-359.
26. Giustina A, Doga M, Bossoni S, et al. Central alpha-2 adrenergic function in patients with essential hypertension. Comparative study of growth hormone (GH) secretion stimulated

- by clonidine and GH-releasing hormone. *Horm Metab Res.* 1990;22(8):451-452. doi:10.1055/s-2007-1004944
27. Giustina A, Doga M, Bodini C, et al. Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects. *Acta Endocrinol (Copenh).* 1990;122(2):206-210. doi:10.1530/acta.0.1220206
 28. Wehrenberg WB, Bergman PJ, Stagg L, Ndon J, Giustina A. Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. *Endocrinology.* 1990;127(6):2705-2708. doi:10.1210/endo-127-6-2705
 29. Giustina A, Girelli A, Buffoli MG, et al. Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. *Diabetes Res Clin Pract.* 1991;14(1):47-54. doi:10.1016/0168-8227(91)90052-f
 30. Giustina A, Bossoni S, Bodini C, et al. The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man. *Metabolism.* 1991;40(5):519-523. doi:10.1016/0026-0495(91)90234-n
 31. Romanelli G, Giustina A, Cravarezza P, Caldonazzo A, Agabiti-Rosei E, Giustina G. Albuminuria induced by exercise in hypertensive type I and type II diabetic patients: a randomised, double-blind study on the effects of acute administration of captopril and nifedipine. *J Hum Hypertens.* 1991;5(3):167-173.
 32. Giustina A, Bossoni S, Bodini C, et al. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease. *Horm Res.* 1991;35(3-4):99-103. doi:10.1159/000181882
 33. Giustina A, Bossoni S, Bodini C, et al. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients. *Acta Endocrinol (Copenh).* 1991;125(5):510-517. doi:10.1530/acta.0.1250510
 34. Giustina A, Girelli A, Alberti D, et al. Effects of pyridostigmine on spontaneous and growth hormone-releasing hormone stimulated growth hormone secretion in children on daily glucocorticoid therapy after liver transplantation. *Clin Endocrinol (Oxf).* 1991;35(6):491-498. doi:10.1111/j.1365-2265.1991.tb00933.x
 35. Giustina A, Buffoli MG, Bussi AR, Wehrenberg WB. Acute effects of clonidine and growth-hormone-releasing hormone on growth hormone secretion in patients with hyperthyroidism. *Horm Res.* 1991;36(5-6):192-195. doi:10.1159/000182159
 36. Wehrenberg WB, Giustina A. Basic counterpoint: mechanisms and pathways of gonadal steroid modulation of growth hormone secretion. *Endocr Rev.* 1992;13(2):299-308. doi:10.1210/edrv-13-2-299
 37. Wehrenberg WB, Wiviott SD, Voltz DM, Giustina A. Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement. *Endocrinology.* 1992;130(3):1445-1450. doi:10.1210/endo.130.3.1347008
 38. Giustina A, Schettino M, Bussi AR, et al. Effect of arginine on the GHRH-stimulated GH secretion in patients with hyperthyroidism. *Horm Res.* 1992;38(5-6):256-259. doi:10.1159/000182554
 39. Giustina A, Girelli A, Licini M, Schettino M, Negro-Vilar A. Thyrotropin and prolactin secretion are not affected by porcine and rat galanin in normal subjects. *Horm Metab Res.* 1992;24(7):351-352. doi:10.1055/s-2007-1003333
 40. Giustina A, Schettino M, Bodini C, Doga M, Licini M, Giustina G. Effect of galanin on the growth hormone response to growth hormone-releasing hormone in acromegaly. *Metabolism.* 1992;41(12):1291-1294. doi:10.1016/0026-0495(92)90098-u

41. Giustina A, Bodini C, Doga M, Schettino M, Pizzocolo G, Giustina G. Galanin decreases circulating growth hormone levels in acromegaly. *J Clin Endocrinol Metab.* 1992;74(6):1296-1300. doi:10.1210/jcem.74.6.1375598
42. Giustina A, Wehrenberg WB. The role of glucocorticoids in the regulation of Growth Hormone secretion: mechanisms and clinical significance. *Trends Endocrinol Metab.* 1992;3(8):306-311. doi:10.1016/1043-2760(92)90142-n
43. Giustina A, Girelli A, Bossoni S, Legati F, Schettino M, Wehrenberg WB. Effect of galanin on growth hormone-releasing hormone-stimulated growth hormone secretion in adult patients with nonendocrine diseases on long-term daily glucocorticoid treatment. *Metabolism.* 1992;41(5):548-551. doi:10.1016/0026-0495(92)90217-x
44. Giustina A, Bussi AR, Legati F, et al. Galanin does not affect the growth hormone-releasing hormone-stimulated growth hormone secretion in patients with hyperthyroidism. *Acta Endocrinol (Copenh).* 1992;127(6):504-508. doi:10.1530/acta.0.1270504
45. Giustina A, Bossoni S, Buffoli MG, et al. Effect of pretreatment with pyridostigmine on the thyrotropin response to thyrotropin-releasing hormone in patients with Cushing's disease. *Horm Metab Res.* 1992;24(5):248-250. doi:10.1055/s-2007-1003305
46. Giustina A, Bussi AR, Conti C, et al. Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects. *Horm Res.* 1992;37(4-5):165-170. doi:10.1159/000182303
47. Giustina A, Buffoli MG, Bussi AR, et al. Comparative effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in adult patients on chronic glucocorticoid therapy. *Horm Metab Res.* 1992;24(5):240-243. doi:10.1055/s-2007-1003302
48. Giustina A, Bossoni S, Bodini C, et al. Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. *J Clin Endocrinol Metab.* 1992;74(6):1301-1305. doi:10.1210/jcem.74.6.1592874
49. Giustina A, Bussi AR, Licini M, Pizzocolo G, Schettino M, Wehrenberg WB. Acute effects of hydrocortisone on circulating growth hormone levels in patients with acromegaly. *Horm Res.* 1992;37(6):212-216. doi:10.1159/000182314
50. Ndon JA, Giustina A, Wehrenberg WB. Hypothalamic regulation of impaired growth hormone secretion in diabetic rats. 1. Studies in streptozotocin-induced diabetic rats. *Neuroendocrinology.* 1992;55(5):500-505. doi:10.1159/000126163
51. Giustina A, Girelli A, Bodini C, et al. Comparative effect of porcine and rat galanin on growth hormone secretion in normal adult men. *Horm Metab Res.* 1992;24(2):90-91. doi:10.1055/s-2007-1003263
52. Ndon JA, Giustina A, Wehrenberg WB. Hypothalamic regulation of impaired growth hormone secretion in diabetic rats. 2. Studies in spontaneously diabetic BB Worcester rats. *Neuroendocrinology.* 1992;55(5):506-511. doi:10.1159/000126164
53. Picotamide, a dual TXB Synthetase inhibitor and TXB Receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. A. Giustina, S. Bossoni, A. Cimino, M.T. Comini, N. Gazzoli, G.B. Leproux, W.B. Wehrenberg, G. Romanelli, G. Giustina. *Diabetes*;42:178-182, 1993
54. Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease. A. Giustina, S. Bossoni, A.R. Bussi, A. Pozzi, W.B. Wehrenberg. *Endocrine Research*, 19:47-56, 1993

55. Effects of sex and age on the growth hormone response to galanin in healthy human subjects.
A. Giustina, M. Licini, A.R. Bussi, A. Girelli, G. Pizzocolo, M. Schettino, A. Negro-Vilar.
Journal of Clinical Endocrinology and Metabolism; 76:1369-1372, 1993
56. Effect of galanin, and arginine, alone or in combination on growth hormone secretion in adult patients treated with glucocorticoids.
A. Giustina, M. Licini, A. Girelli, A.R. Bussi, W.B. Wehrenberg.
Neuroendocrinology; 57:843-848, 1993
57. Isradipine decreases exercise-induced albuminuria in patients with essential hypertension.
A. Giustina, S. Bossoni, C. Macca, G. Romanelli.
Renal Failure; 15:509-514, 1993
58. Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly.
A. Giustina, M. Doga, A.R. Bussi, M. Licini, M. Schettino.
Acta Endocrinologica; 128:131-135, 1993
59. Hypothalamic regulation of growth hormone secretion during food deprivation in the rat.
B.A. Janowski, N.C. Ling, A. Giustina, W.B. Wehrenberg.
Life Sciences; 52:981-987, 1993
60. The biological potency of equimolar amounts of somatostatin-14 and somatostatin-28 in rats.
D.M. Volts, A. Giustina, R.C. Gaillard, W.B. Wehrenberg.
Endocrine Journal; 1:235-239, 1993
61. Effects of metoclopramide on the paradoxical growth hormone response to galanin in acromegaly.
A. Giustina, M. Doga, C. Bodini, S. Bossoni, E. Bresciani, A.R. Bussi.
Endocrine Research; 19:303-315, 1993
62. Variability in the growth hormone response to growth hormone releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients.
A. Giustina, C. Bodini, S. Bossoni, U. Valentini, W.B. Wehrenberg.
Journal of Endocrinological Investigation; 16:585-590, 1993
63. Effects of metoclopramide on the growth hormone response to galanin in normal man.
A. Giustina, A.R. Bussi, M. Doga, M. Licini, M. Schettino, W.B. Wehrenberg.
Hormone and Metabolic Research; 25:457-506, 1993
64. Arginine blocks the inhibitory effects of hydrocortisone on circulating growth hormone levels in patients with acromegaly.
A. Giustina, M. Schettino, S. Bossoni, A.R. Bussi, M. Doga, M. Licini, W.B. Wehrenberg.
Metabolism,42:664-668,1993
65. Physiological role of galanin in the regulation of anterior pituitary function in humans.
A. Giustina, M. Licini, M. Schettino, M. Doga, G. Pizzocolo, A. Negro-Vilar.
American Journal of Physiology, 266:(29) E57-E61, 1994
66. Acute effects of octreotide, a long-acting somatostatin analog, on insulinemic and glycemic response to a mixed meal in patients with essential obesity. A. dose-response study.
A. Giustina, A.R. Bussi, G. Pizzocolo, A. Cimino, G. Giustina.
Diabetes Nutrition and Metabolism, 7:35-41, 1994

67. Growth hormone neuroregulation in diabetes mellitus.
A. Giustina, W.B. Wehrenberg.
Trends in Endocrinology and Metabolism, 5:73-78, 1994
68. Effect of long-term administration of picotamide on baseline and exercise-induced urinary albumin excretion in patients with type II diabetes mellitus and incipient nephropathy.
A. Giustina, P. Ianniello, S. Bossoni, M.T. Comini, P. Desenzani, N. Gazzoli, G. Romanelli.
Clinical Therapeutics, 16:191-199, 1994
69. Effect of hydrocortisone on the growth hormone (GH) response to GH-releasing hormone in acromegaly.
A. Giustina, A.R. Bussi, M. Doga, W.B. Wehrenberg.
Hormone Research, 41:33-37, 1994
70. Acute and chronic effect of systemic administration of interleukin-1B and endotoxin on the hypothalamic-pituitary adrenal axis in the rat.
W.B. Wehrenberg, P. Saudan, R. Corder, D.M. Voltz, A. Giustina, R.C. Gaillard.
Endocrine Journal, 2:273-277, 1994
71. Effect of galanin on the growth hormone (GH) response to thyrotropin-releasing hormone (TRH) in patients with acromegaly.
A. Giustina, A.R. Bussi, E. Bresciani, M. Doga, M. Licini, M. Schettino, G. Giustina.
Neuroendocrinology Letters, 16:151-158
72. Hexarelin (His-D-2Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂), a new GH-releasing peptide, is biologically active in male and female rats.
L.K. Conley, A. Giustina, B.P. Imbimbo, L.C. Stagg, R. Deghenghi, W.B. Wehrenberg.
Endocrine Journal, 2: p. 691-695, 1994
73. Effect of the combined administration of galanin and clonidine on serum growth hormone levels in normal subjects and in patients under chronic glucocorticoid treatment.
A. Giustina, S. Bossoni, M. Licini, C. Macca, G. Milani, W.B. Wehrenberg.
Endocrine Research, 20:151-164, 1994
74. Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II diabetic patients.
A. Giustina, E. Bresciani, C. Tassi, A. Girelli, U. Valentini.
Metabolism. Vol 43 (7) p. 893-898. 1994.
75. Reciprocal relationships between the level of circulating cortisol and the growth hormone responsiveness to growth hormone releasing hormone in man. Studies in hypoadrenal patients.
A. Giustina, E. Bresciani, S. Bossoni, M. Doga, V. Misitano, W.B. Wehrenberg.
Journal of Clinical Endocrinological and Metabolism. Vol. 79 (5) p 1266-1272. 1994.
76. Serum lipoprotein(a) is not increased in niddm patients with microalbuminuria.
A. Girelli, A. Cimuno, L. Rocca, A. salvi, S. Spandrio, U. Valentini, A. Giustina.
Diabetes Care. Vol. 17 (5) p. 456-457. 1994.
77. Effects of pirydostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly.
A. Giustina, A.R. Bussi, M. Doga, C. Iacobello, W.B. Wehrenberg.
Hormone and Metabolic Research Vol 26, (6) p. 288-392. 1994.
78. Effects of beta2-agonist during cardiopolmonary exercise test in COPD patients.
M. Malerba, E. Boni, G. Romagnoni, B. Filippi, A. Politi, A. Giustina, C. Tantucci, V.

- Grassi.
Monaldi Archives of Chest Diseases, 49: 389-393, 1994
79. Inhibitory effect of galanin on growth hormone releases from rat pituitary tumor cells (GH1) in culture.
A. Giustina, C. Bonfanti, M. Licini, C. De Rango, G. Milani.
Life Sciences, 55: p. 1845-1851, 1994
80. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone.
A. Giustina, A.R. Bussi, C. Jacobello and W.B. Wehrenberg.
Journal of Clinical Endocrinology and Metabolism, 80: 122-129, 1995
81. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
A. Giustina, E. Bresciani, A.R. Bussi, A. Bollati, C. Bonfanti, G. Bugari, L. Chiesa and G. Giustina.
Journal of Clinical Endocrinology and Metabolism, 80: 1333-1340, 1995
82. Changes in the growth hormone axis due exercise training in male and female rats: secretory and molecular responses.
J.A. Butkus, R.S. Brogan, A. Giustina, G. Kastello, M. Sothmann and W.B. Wehrenberg.
Endocrinology, 36: 2664-2670, 1995
83. Cardiopulmonary adaptation to exercise after acute weight loss in severely obese subjects.
E. Boni, A. Giustina, E. Borra, A.R. Bussi, V. Grassi.
Monaldi Archives of Chest Disease, 50: 264-268, 1995
84. Hexarelin, a novel GHRH-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly.
A. Giustina, E. Bresciani, G. Bugari, A.R. Bussi, R. Deghenghi, B. Imbimbo, G. Giustina.
Endocrine Research, 21: 569-582, 1995
85. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers.
B.P. Imbimbo, M. Licini, M. Schettino, A. Mosca, E. Onelli, L. Zecca, A. Giustina.
The Journal of Clinical Pharmacology, 35: 285-290, 1995
86. Effect of glucocorticoids on the paradoxical growth hormone response to thyrotropin-releasing hormone in patients with acromegaly.
A. Giustina, M. Doga, E. Bresciani, A.R. Bussi, L. Chiesa, V. Misitano and G. Giustina.
Metabolism, 44: 379-383, 1995
87. Adrenergic and cholinergic involvement in basal and growth hormone-releasing hormone-stimulated growth hormone secretion in glucocorticoid-treated rats.
A. Giustina, V. Misitano, D. Voltz, A. Piering, W.B. Wehrenberg.
Endocrine Research, 21: 719-732, 1995
88. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in human with or without glucocorticoid excess.
A. Giustina, A.R. Bussi, R. Deghenghi, B. Imbimbo, M. Licini, C. Poiesi, W.B. Wehrenberg.
Journal of Endocrinology, 146: 2227-2232, 1995
89. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.

- A. Giustina, E. Boni, G. Romanelli, V. Grassi, G. Giustina.
The American Journal of Cardiology, 75: 1042-1047, 1995
90. Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women.
A. Giustina, C. Gastaldi, G. Bugari, L. Chiesa, G. Loda, C. Tironi, A. Negro-Vilar.
Metabolism, 44: 1028-1032, 1995
 91. Effect of two B₂-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis.
A. Giustina, M. Malerba, E. Bresciani, P. Desenzani, M. Licini, G. Zaltieri and V. Grassi.
Journal of Endocrinological Investigation, 18:847-852, 1995
 92. Influence of thyroid hormones on the regulation of growth hormone secretion.
A. Giustina and W.B. Wehrenberg.
European Journal of Endocrinology, 133: 646-653, 1995
 93. Galanin counteracts the inhibitory effects of glucocorticoids on growth hormone secretion in the rat.
A. Giustina, D.M.Voltz, J. Teik, W.B. Wherenberg.
Metabolism, Vol 44, (2), p.224-227. 1995.
 94. Effect of GHRP-6 and GHRH on GH secretion in rats following chronic glucocorticoid treatment.
D.M.Voltz, A.W. Piering, M. Magestro, A. Giustina, W.B. Wherenberg.
Life Sci. Vol.56, (7), p. 491-497. 1995.
 95. Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat.
L.K. Conley, J.A. Teik, R. Deghenghi, B.P. Imbimbo, A. Giustina, V. Locatelli, W.B. Wherenberg.
Neuroendocrinology. Vol. 61, (1) p. 44-50. 1995.
 96. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy.
A. Giustina, R. Lorusso, V. Borghetti, G. Bugari, V. Misitano and O. Alfieri.
American Heart Journal, 131/3: 629-622, 1996
 97. Effect of galanin on growth hormone (GH) response to thyrotropin releasing hormone of rat pituitary GH-secreting adenomatous cells (GH1) in culture.
A. Giustina, C. Bonfanti, M. Licini, B. Stefana, G. Ragni, A. Turano.
Life Sciences, 58: 83-90, 1996
 98. Immunocytochemical and molecular analysis of the effects of glucocorticoid treatment on the hypothalamic-somatotropic axis in the rat.
S.K. Fife, R.S. Brogan, A. Giustina, W.B. Wehrenberg.
Neuroendocrinology, 64:131-138, 1996.
 99. Hypothalamic control of GH secretion in type 1 diabetic men: effect of the combined administration of growth hormone (GH)-releasing hormone and Hexarelin, a novel GHRP-6 analog.
A. Giustina, P. Desenzani, P. Perini, R. Deghenghi, G. Bugari, W.B. Wehrenberg, G. Giustina.
Endocrine Research, 22:159-174, 1996.
 100. The Pharmacological Aspects Of The Treatment Of Acromegaly.
A. Giustina, G. Zaltieri, F. Negrini, and W.B. Wehrenberg.
Pharmacological Research, Vol.34, p.247-268, 1996.
 101. Glutamate Decarboxylase Autoimmunity and Growth Hormone Secretion in Type I Diabetes Mellitus.

- A. Giustina, P. Desenzani, P. Perini, E. Bazzigaluppi, C. Bodini, S. Bossoni, C. Poiesi, W. B. Wehrenberg, and E. Bosi.
Metabolism, Vol. 46, N. 4, p. 382-387, 1997.
102. Inhibitory Effects of Galanin on Growth Hormone (GH) Release in Cultured GH-Secreting Adenoma Cells: Comparative Study With Octreotide, GH-Releasing Hormone, and Thyrotropin-Releasing Hormone.
 A. Giustina, G. Ragni, A. Bollati, R. Cozzi, M. Licini, C. Poiesi, S. Turazzi, and C. Bonfanti.
Metabolism, Vol. 46, N. 4, p.425-430, 1997.
 103. Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone.
 A. Giustina, C. Bonfanti, M. Licini, G. Ragni, B. Stefana.
Regulatory Peptides Vol 70, p. 49-54, 1999.
 104. Haemodynamic effects of intravenous growth hormone in congestive heart failure.
 M. Volterrani, P. Desenzani, R. Lorusso, A. D'Aloia, F. Manelli, A. Giustina.
The Lancet. Vol. 349, N. 9058, p.1067-1068, 1997.
 105. Growth hormone in end-stage heart failure.
 A. Giustina, M. Volterrani, P. Desenzani.
The Lancet.Vol. 349, N. 9068, p.1843, 1997.
 106. Maturation of the Regulation of Growth Hormone Secretion in Young Males with Hypogonadotropic Hypogonadism Pharmacologically Exposed to Progressive Increments in Serum Testosterone.
 A. Giustina, T. Scavini, C. Tassi, P. Desenzani, C. Poiesi, W.B.Wehrenberg, A.D. Rogol, and J.D. Veldhuis.
Journal of Clinical Endocrinology and Metabolism. Vol. 82, n 4, p 1210-1219. 1997.
 107. Effects of Food Deprivation on the GH Axis: Immunocytochemical and molecular Analysis.
 R. S. Brogan, S. K. Fife, L. K. Conley, A. Giustina, W. B. Wehrenberg.
Neuroendocrinology, 65: 129-135, 1997.
 108. Modulation by Galanin of Growth Hormone and Gonadotropin Secretion from Perfused Pituitary and Median Eminence of Prepubertal Male Calves.
 M. Baratta, R. Saleri, C. Mascadri, D. H. Coy, A. Negro-Vilar, C. Tamanini, A. Giustina.
Neuroendocrinology, 66: 271-277, 1997.
 109. Physiological Role of the Opioid-Cholinergic Interaction in Growth Hormone Neuroregulation: Effect of Sex and Food Intake.
 L. De Marinis, A. Mancini, D. Valle, C. Fiumara, G. Conte, A. Bianchi, M. Perrelli, R. Gentilella, A. Giustina.
Metabolism, Vol. 46, N. 7, pp. 740-744, 1997.
 110. Effects of tamoxifen on GH and IGF-I levels in Acromegaly.
 R. Cozzi, R. Attanasio G. Oppizzi, P. Orlandi, A. Giustina, S. Lodrini, N. Da Re, and D. Dallabonzana.
Journal of Endocrinological Investigation. 20: 445-451, 1997.
 111. Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.
 L. K. Conley, R. C. Gaillard, A. Giustina, R. S. Borgan, W. B. Wehrenberg.
Journal of Endocrinology, 158, 367-375, 1998.
 112. Long-Term Treatment with the Dual Antithromboxane Agent Picotamide Decreases Microalbuminuria in Normotensive Type 2 Diabetic Patients.
 A. Giustina, P. Perini, P. Desenzani, S. Bossoni, P. Ianniello, M. Milani, G. Davi, G.

- Romanelli.
Diabetes, Vol. 47, N 3, p.423-430. 1998.
113. Growth, Insulin-Like Growth Factor I (IGF-I), and IGF-Binding Proteins 1 and 3 in Children with Severe Liver Disease before and after Liver Transplantation: A Longitudinal and Cross-Sectional Study.
F. Buzi, A. M. Bontempelli, D. Alberti, J. Jones, A. Pilotta, A. M. Lombardi, A. Giustina, M. A. Preece.
Pediatric Research, Vol. 43, N. 4, p. 478-483. 1998.
 114. Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human.
A. Giustina, J. Veldhuis.
Endocrine Reviews 19(6):717-797, 1998
 115. Short-Term glucocorticoid administration decreases both hypothalamic and pituitary galanin synthesis in adult male rat.
R.S. Brogan, L.K. Coney, W.B. Wehrenberg, G. Beretta, and A. Giustina.
Metabolism, Vol. 48, N 6, p 792-796. 1999.
 116. Effects of galanin infusion on GH secretion and GHRH-induced GH release in prepubertal male lambs.
R. Saleri, M. Baratta, R. Renaville, D. Portetelle, D.H. Coy, A. Giustina, C. Tamanini.
Small Ruminant Research, 33 , 231-237. 1999.
 117. Cardiovascular effects of a single slow release Lanreotide injection in patients with acromegaly and left ventricular hypertrophy.
F. Manelli, P. Desenzani, E. Boni, G. Bugari, F. Negrini, G. Romanelli, V. Grassi, and A. Giustina.
Pituitary; 2:205-210. 1999.
 118. Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generate immunoreactive insulin-like growth factor I.
S.B. Solerte, M. Fioravanti, G. Vignati, A. Giustina, L. Cravello, and E. Ferrari.
The Journal of Clinical Endocrinology e Metabolism, Vol 84, N 9, 3260-3267. 1999.
 119. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure.
A. Giustina, M. Volterrani, F. Manelli, P. Desenzani, C. Poiesi, R. Lorusso, and A. Giordano.
American Heart Journal, Vol 137, N 6, p 1035-1043, 1999.
 120. Growth Hormone (GH) responses to GH-releasing hormone alone or combined with Arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergetic tone.
M. Terzolo, S. Bossoni, A. Alì, M. Doga, G. Reimondo, G. Milani, P. Peretti, F. Manelli, A. Angeli, and A. Giustina.
The Journal of Clinical Endocrinology and Metabolism. Vol 85, N 3, p. 1310-1315. 2000.
 121. Effects of Galanin on Growth hormone and Prolactin Secretion in Anorexia Nervosa.
L. De Marinis, A. Mancini, D. Valle, A. Bianchi, R. Gentilella, D. Milardi, C. Mascadri, and A. Giustina.
Metabolism. Vol. 49, N 2, p. 155-159. 2000.
 122. Exercise-induced microalbumunuria in patients with active acromegaly. Acute, effects of slow-release Lanreotide, a long-acting Somatostating analog.
F. Manelli, S. Bossoni, A. Burattin, M. Doga, S.B. Solerte, G. Romanelli, and A. Giustina.
Metabolism, Vol.49, N 5. p. 634-639. 2000.

123. Acute and chronic galanin administration decreases hypothalamic galanin synthesis in both male and female, adult rats. Evidence for a long-loop galanin autofeedback.
A. Giustina, R. Brogan, L. Conley, D. Godi, F. Manelli, and W.B. Wehrenberg.
Metabolism, Vol.49, N 6, p. 778-783. 2000.
124. Glucocorticoid-induced Osteoporosis.
F. Manelli, and A. Giustina.
Trends in Endocrinology and Metabolism. TEM Vol 11, N 3, p 79-85. 2000.
125. CONSENSUS. Criteria for Cure of Acromegaly: A Consensus Statement.
A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, J. Veldhuis, J. Wass, K. Von Werder, and S. Melmed.
The Journal of Clinical Endocrinology and Metabolism. Vol 85, N 2, p. 526-529. 2000.
126. Strategies for appraising suspected growth hormone, deficiency in the adult.
J. Veldhuis, A. Giustina.
The Endocrinologist . Vol.10: p.34-50. 2000.
127. The Effects of a Continuous Infusion of Exsarelin on Pulsatile Growth Hormone Release, Growth Axis and Galanin Gene Expression and on the Response of the Growth Axis to Growth Hormone-Releasing Hormone.
L.K. Conley, R.S. Brogan, A. Giustina, and W.B. Wehrenberg.
Pituitary . Vol 2, N 4, p. 253-260. 2000.
128. Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion.
G. Del Rio, A. Velardo, C. Mascadri, G. Zaltieri, G. Papi, R. Menozzi, A. Giustina.
European Journal of Endocrinology. 142:179-186, 2000
129. Role of food intake in the modulation of Hexarelin-induced growth hormone release in normal human subjects.
L. De Marinis, A. Mancini, D. Valle, D. Izzi, A. Bianchi, R. Gentilella, A. Giampietro, P. Desenzani, A. Giustina.
Hormone and Metabolic Research. vol. 32, p. 152-156. 2000.
130. Role of Growth Hormone in Chronic Heart Failure.
(Therapeutic Implications)
M. Volterrani, F. Manelli, M. Ciccoira, R. Lorusso and A. Giustina
Drugs 2000. 60:711-719, 2000.
131. Somatostatin analogs selective for subtype 2 and 5 of the somatostatin receptor suppress with different patterns growth hormone (GH) secretion in human GH-secreting adenoma cells cultured in vitro.
G. Tulipano, C. Bonfanti, G. Milani, B. Billeci, A. Bollati, R. Cozzi, G. Maira, W.A. Marphy, C. Poiesi, S. Turazzi, A. Giustina.
Neuroendocrinology. 73: p. 344-351. 2001.
132. Glucocorticoid-Induced Osteoporosis: summary of a workshop.
E. Canalis, A. Giustina.
The Journal of Clinical Endocrinology and Metabolism. Vol. 86, p 5681-5685, 2001.
133. IGF-1, IGFBP-2 and -3 but not GH concentrations are different in normal and poor growing piglets.
R. Saleri, M. Baratta, G.L. Mainardi, R. Renaville, A. Giustina, F. Quintavalla, C. Tamanini.
Reproduction Nutrition Development vol. 41, (2) p. 163-172. 2001.
134. Acquired growth hormone resistance in patients with chronic heart failure: implication for therapy with growth hormone.

- S.D. Anker, M. Volterrani, C.D. Pflaum, C.J. Strasburger, K.J. Osterziel, W. Doehner, M.B. Ranke, P.A. Poole-Wilson, A. Giustina, R. Dietz, A.J.S. Coats. Journal of the American College of Cardiology. Vol 38, p. 443-452, 2001.
135. Primary Lymphoma of the pituitary. an emerging clinical entity. A. Giustina, M. Gola, M. Doga, and E. Agabiti Rosei. The Journal of Clinical Endocrinology and Metabolism. 86 (10), p. 4567-4575.2001.
136. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis. M. Doga, S. Bonadonna, A. Burattin, R. Carpinteri, F. Manelli, A. Giustina. Front Horm Res. Vol 30, p. 150-164. 2002.
137. Growth hormone in glucocorticoid induced osteoporosis. F. Manelli, S. Bonadonna, A. Burattin, S. Bossoni, E. Agabiti Rosei, A. Giustina. Front Horm Res. Vol 30, p. 174-183. 2002.
138. Long-term effects of lanreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. G. Amato, G. Maziotti, M. Rotondi, S. Iorio, M. Doga, F. Sorvillo, G. Manganella, F. Di Salle, A. Giustina, C. Carella. Clinical Endocrinology Vol 56, p.65-71, 2002.
139. Leptin regulates GH gene expression and secretion and nitric oxide production in pig pituitary cells. M. Baratta, R. Saleri, G.L. Mainardi, D. Valle, A. Giustina C. Tamanni. Endocrinology. Vol. 143, p.551-557, 2002.
140. Preoperative Growth Hormone response to Thyrotropin-Releasing Hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. L. De Marinis, A. Mancini, A. Bianchi, A. Gentilella, D. Valle, A. Giampietro, P. Zuppi, C. Anile, G. Maira, A. Giustina. Metabolism, Vol. 51 (5) p. 616-621. 2002.
141. A. retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin. L. De Marinis, P. Zuppi, D. Valle, A. Mancini, A. Bianchi, L. Lauriola, P. Pasquini, C. Anile, G. Maira, A. Giustina. Hormone and Metabolic Research. Vol. 34, p.137- 143, 2002.
142. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. G. Tulipano, D. Soldi, M. Bagnasco, M.D. Culler, J.E. Taylor, D. Cocchi, and A. Giustina. Endocrinology 143 (4), p.1218-1224, 2002.
143. CONSENSUS. Guidelines for acromegaly management. S. Melmed, F.F. Casanueva, F. Cavagnini, P. Chanson, L. Frohman, A. Grossman, K. Ho, D. Kleinberg, S. Lamberts, E. Laws, G. Lombardi, M.L. Vance, K. Von Werder, J. Wass and A. Giustina, for the Acromegaly Treatment Consensus Workshop Participants. The Journal of Clinical Endocrinology and Metabolism. Vol 87, N 9, p. 4054-4058. 2002.
144. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. M.A. Ambrosio, P. Franceschetti, M. Bondanelli, M. Doga, P. Maffei, R. Baldelli, G. Tamburrano, N. Siculo, A. Giustina, and E. degli Uberti. Metabolism vol. 51, n 3, p 387-393, 2002.
145. Growth hormone secretagogue (GHS) analogue, hexarelin stimulated GH from peripheral lymphocytes.

- L. Poppi, V.D. Dixit, M. Baratta, A. Giustina, C. Tamanni, N. Parvizi.
Experimental and Clinical Endocrinology & Diabetes. Vol 10, p. 343-347, 2002.
146. Consensus document on substitution therapy with testosterone in hypoandrogenic elderly men.
 G. Valenti, S. Bossoni, A. Giustina, D. Maugeri, M. Motta, G. B. Vigna, R. Fellin, F. Corica, A. Corsonello, G. Paolisso, M. Barbagallo, L. Dominguez, L. Denti, GP.Ceda, E. Ferrari, B. Pontiggia, F. Strollo.
Aging clinical and experimental research. Vol. 14, p. 439-464. 2002.
147. Preliminary observation on the effect of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart.
 R. Lorusso, E. Pasini, A. Cargnoni, C. Cecconi, M. Volterrani, A. Burattin D. Valle, R. Ferrari and A. Giustina.
Journal of Endocrinological Investigation . Vol. 26, N 1, p.RC1-RC4. 2003.
148. Acromegaly consensus the next step
 A. Giustina, S. Melmed.
The Journal of Clinical Endocrinology and Metabolism. Vol 88, N 4, p.1913-1914. 2003
149. Development of meningioma in a patient with acromegaly during octreotide treatment. Are there any causal relationships ?
 E. De Menis, G. Tulipano, S. Villa, D. Billeci, C. Bonfanti, P. Pollara, P. Pauletto, A. Giustina.
Journal Endocrinological Investigation. Vol. 26, p.359-363, 2003.
150. Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma causing high levels of insulin-like growth factor 1 (IGF-1).
 A. Tucci, S. Bonadonna, C. Cattaneo, M. Ungari, A. Giustina, and G. Rossi.
Leukemia & Lymphoma. Vol 44 n° 3 p 543-545. 2003.
151. Diagnosis and treatment of acromegaly complications.
 A. Giustina F.F. Casanueva, F. Cavagnini, P. Chanson, D. Clemmons, L.A. Frohman, R. Gaillard, K. Ho, P. Jaquet, D.L. Kleinberg, S.W. Lamberts, G. Lombardi, M. Sheppard, C.J. Strasburger, M.L. Vance, J. Wass, S. Melmed.
Journal Endocrinological Investigation, Vol 26 N 12. p.1242-1247. 2003
152. Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits.
 R. Lorusso, S. Pentiricci, R. Raddino, T.M. Scarabelli, V. Villanucci, A. Burattin, G. Romanelli, S. Casari, R. Scelsi, A. Giustina.
Diabetes Vol 52 p 2814-2820. 2003.
153. Diagnosis and complications of Cushing's syndrome: a consensus statement.
 G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro.
Journal of Clinical Endocrinology and Metabolism, Vol 88 N 12. p.5593-5602. 2003
154. Perspectives on glucocorticoid-induced osteoporosis.
 E. Canalis, J.P. Bilezikian, A. Angeli A. Giustina.
Bone. Vol. 34 (8), p 593-8. 2004.
155. Leptin stimulates growth hormone secretion via a direct pituitary effect combined with a Decreases somatostatin tone in a median eminence-pituitary perfusion study.
 R. Saleri, A. Giustina, C. Tamanini, D. Valle, A. Burattin, W.B. Wehrenberg, M. Baratta.
Neuroendocrinology. Vol. 79 (4) p. 221-228. 2004.

156. Effects of the selective estrogen receptor modulator (SERM) LY117018 on growth hormone (GH) secretion: in vitro study.
G. Tulipano, C. Bonfanti, C. Poiesi, A. Burattin, S. Turazzi, G. Barone, R. Cozzi, A. Bollati, D. Valle, A. Giustina.
Metabolism. Vol.53, N 5, p. 563-570. 2004.
157. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries.
D. Rizzoni, E. Porteri, A. Giustina, C. De Ciuceis, I. Sleiman, G.E. Boari, C. Castellano, M.L. Muiesan, S. Bonadonna, A. Burattin, B. Cerudelli, E. Agabiti-Rosei.
Hypertension. Vol. 43, N 3, p. 561-565. 2004
158. Primary pituitary lymphoma: a clinical-pathological update.
M. Gola, M. Doga, S. Bonadonna, A. Giustina
The Endocrinologist. 14(5):288-292, 2004
159. Glucocorticoids and bone: cellular, metabolic and endocrine effects.
M. Doga, S. Bonadonna, A. Giustina.
Hormones. Vol 3, N° 3, p.184-190. 2004
160. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
G. Amato, G. Mazziotti, F. Sorvillo, M. Piscopo, E. Lali, B. Biondi, S. Iorio, A. Molinari, A. Giustina, C. Carella.
Bone, Vol. 35, n 3, p. 785-791. 2004.
161. Cushing's syndrome and bone.
Mancini T, Doga M, Mazziotti G, Giustina A.
Pituitary. 2004;7(4):249-52.
162. Chronic glucocorticoid treatment alter spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects.
S. Bonadonna, A. Burattin, M. Nuzzo, G. Bulgari, E. Agabiti-Rosei, D. Valle, N. Iori, G.P. Bilezikian, J.D. Veldhuis and A. Giustina.
European Journal of Endocrinology. 152: N° 2 p. 199-205, 2005
163. Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment.
M. Malerba, S. Bossoni, A. Radaeli, E. Mori, S. Bonadonna, A. Giustina and C. Tantucci.
Chest Vol. 27 p. 515-521. 2005.
164. Current guidelines for adult GH replacement.
M. Doga, S. Bonadonna, M. Gola, S.B. Solerte, G. Amato, C. Carella and, A. Giustina.
Reviews in Endocrine & Metabolic Disorders. Vol 6, p 63-70. 2005
165. Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate.
Solerte SB, Ferrari E, Cuzzoni G, Locatelli E, Giustina A, Zamboni M, Schifino N, Rondanelli M, Gazzaruso C, Fioravanti M.
Dementia Geriatric Cognitive Disorders. 19(1): p. 1-10. 2005.
166. The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.
Tulipano G, Rossi E, Culler MD, Taylor JE, Bonadonna S, Locatelli V, Cocchi D, Giustina A.
Regulatory Peptides 2005 ;125(1-3):85-92.

167. Clinical review: Growth hormone and cardiovascular risk factors.
Gola M, Bonadonna S, Doga M, Giustina A.
Journal of Clinical Endocrinology and Metabolism. 2005 ;90(3):1864-70.
168. Ghrelin regulates proliferation and differentiation of osteoblastic cells.
Maccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C, Cocchi D.
Journal of Endocrinology 2005 ;184(1):249-56.
169. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C.
Journal of Bone and Mineral Research 2005 ;20(3):480-6.
170. Primary empty sella.
De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A.
Journal of Clinical Endocrinology and Metabolism. 2005 ;90(9):5471-7.
171. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M, Bonadonna S, Ambrosio MR, Doga M, Gola M, Onofri A, Zatelli MC, Giustina A, degli Uberti EC.
Metabolism. 2005 ;54(9):1174-80.
172. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.
Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A.
J Bone Miner Res. 2005 ;20(10):1837-44.
173. Cardiovascular risk in aging and obesity: is there a role for GH.
Gola M, Bonadonna S, Doga M, Mazziotti G, Giustina A.
J Endocrinol Invest. 2005 ;28(8):759-67.
174. Consensus statement: medical management of acromegaly.
Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A.
Eur J Endocrinol. 2005 ;153(6):737-40.
175. Bone ultrasonometric features and growth hormone secretion in asthmatic patients during chronic inhaled corticosteroid therapy.
Malerba M, Bossoni S, Radaeli A, Mori E, Romanelli G, Tantucci C, Giustina A, Grassi V.
Bone. 2006 Jan;38(1):119-2
176. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients.
Gazzaruso C, Pujia A, Solerte SB, Amici ED, Emanuele E, Falcone C, Geroldi D, Giustina A, Garzaniti A.
Int J Impot Res. 2006 May-Jun;18(3):311-5.
177. Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus.
Gazzaruso C, Solerte SB, De Amici E, Mancini M, Pujia A, Fratino P, Giustina A, Garzaniti A.
Am J Cardiol. 2006 Jan 15;97(2):236-9.

178. Resistance to somatostatin analogs in acromegaly: an evolving concept?
Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A.
J Endocrinol Invest. 2006 Jan;29(1):86-93.
179. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A.
Bone. 2006 Aug;39(2):253-9.
180. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.
Mazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, De Marinis L, Giustina A.
J Bone Miner Res. 2006 Apr;21(4):520-8.
181. Glucocorticoid-induced osteoporosis: an update.
Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A.
Trends Endocrinol Metab. 2006 May-Jun;17(4):144-9
182. Development of Graves' hyperthyroidism during the early phase of pregnancy in a patient with pre-existing and long-standing Hashimoto's hypothyroidism.
Gola M, Doga M, Mazziotti G, Bonadonna S, Giustina A.
J Endocrinol Invest. 2006 Mar;29(3):288-90.
183. Active acromegaly enhances spontaneous parathyroid hormone pulsatility.
Mazziotti G, Cimino V, De Menis E, Bonadonna S, Bugari G, De Marinis L, Veldhuis JD, Giustina A.
Metabolism. 2006 Jun;55(6):736-40.
184. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A.
Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73.
185. Thyroid autoimmunity and spontaneous cervical artery dissection.
Pezzini A, Del Zotto E, Mazziotti G, Ruggeri G, Franco F, Giossi A, Giustina A, Padovani A.
Stroke. 2006 Sep;37(9):2375-7.
186. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A.
Pituitary. 2006; 9: 221-9
187. Consensus Document on substitution therapy with DHEA in the elderly.
Valenti G, Denti L, Sacco M, Ceresini G, Bossoni S, Giustina A, Maugeri D, Vigna GB, Fellin R, Paolisso G, Barbagallo M, Maggio M, Strollo F, Bollanti L, Romanelli F, Latini M.
Aging Clin Exp Res. 2006 Aug;18(4):277-300.
188. Growth hormone deficiency in the adult.
Doga M, Bonadonna S, Gola M, Mazziotti G, Giustina A.
Pituitary. 2006;9(4):305-11
189. Development of acromegaly in a patient with anorexia nervosa: Pathogenetic and diagnostic implications.

- de Menis E, Gola M, Giustina A.
Journal of Endocrinological Investigation 2006 Oct;29(9):821-5.
190. Mechanisms of anabolic therapies for osteoporosis.
Canalis E, Giustina A, Bilezikian JP.
N Engl J Med. 2007 Aug 30;357(9):905-16.
 191. Does growth hormone replacement therapy improve cardiac function?
Giustina A.
Nat Clin Pract Endocrinol Metab. 2007 Sep;3(9):614-5.
 192. Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.
Tulipano G, Taylor JE, Halem HA, Datta R, Dong JZ, Culler MD, Bianchi I, Cocchi D, Giustina A.
Pituitary. 2007;10(3):267-74.
 193. Glucocorticoid-induced osteoporosis: pathophysiology and therapy.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP.
Osteoporos Int. 2007 Oct;18(10):1319-28
 194. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A.
Pituitary. 2007;10(3):227-32.
 195. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P.
J Clin Endocrinol Metab. 2007 May;92(5):1743-7.
 196. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG.
Lorusso R, De Cicco G, Beghi C, Gherli T, Poli E, Corradi D, Maestri R, Bonadonna S, Mancini T, Giustina A.
Int J Cardiol. 2007 May 31;118(2):164-9.
 197. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.
Mazziotti G, Giustina A, Canalis E, Bilezikian JP.
Arq Bras Endocrinol Metabol. 2007 Nov;51(8):1404-12.
 198. Pegvisomant in acromegaly: why, when, how.
Colao A, Arnaldi G, Beck-Peccoz P, Cannavò S, Cozzi R, degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R, Ghigo E.
J Endocrinol Invest. 2007 Sep;30(8):693-9.
 199. The management of the patient with acromegaly and headache: a still open clinical challenge.
Giustina A, Gola M, Colao A, De Marinis L, Losa M, Siculo N, Ghigo E.
J Endocrinol Invest. 2008 Oct;31(10):919-24.
 200. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.
Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S; Pituitary Society; European Neuroendocrine Association.
J Endocrinol Invest. 2008 Sep;31(9):820-38.

201. Prevention and treatment of glucocorticoid-induced osteoporosis.
Doga M, Mazziotti G, Bonadonna S, Patelli I, Bilezikian JP, Canalis E, Giustina A.
J Endocrinol Invest. 2008 Jul;31(7 Suppl):53-8.
202. Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.
Giustina A, Mancini T, Boscani PF, de Menis E, degli Uberti E, Ghigo E, Martino E, Minuto F, Colao A; COM.E.T.A. (COMorbidities Evaluation and Treatment inAcromegaly) Italian Study Group.
J Endocrinol Invest. 2008 Aug;31(8):731-8.
203. Prevalence of vertebral fractures in men with acromegaly.
Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L, Giustina A.
J Clin Endocrinol Metab. 2008 Dec;93(12):4649-55
204. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.
Davi' MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G.
Eur J Endocrinol. 2008 Nov;159(5):533-40
205. Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test.
Mazziotti G, Bonadonna S, Doga M, Patelli I, Gazzaruso C, Solerte SB, De Menis E, Giustina A.
Neuroendocrinology. 2008;88(4):299-304.
206. Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia.
Solerte SB, Gazzaruso C, Bonacasa R, Rondanelli M, Zamboni M, Basso C, Locatelli E, Schifino N, Giustina A, Fioravanti M.
Am J Cardiol. 2008 ;101(11A):69E-77E
207. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.
Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, Salvucci F, Valenti C, Giustina A, Garzaniti A.
J Am Coll Cardiol. 2008 May 27;51(21):2040-4.
208. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L.
J Clin Endocrinol Metab. 2008 Jul;93(7):2746-50.
209. Growth hormone, insulin-like growth factors, and the skeleton.
Giustina A, Mazziotti G, Canalis E.
Endocr Rev. 2008 Aug;29(5):535-59.
210. Pituitary testing: a reappraisal.
Giustina A.
Pituitary. 2008;11(2):113-4.

211. Hyperprolactinemia and prolactinomas.
Mancini T, Casanueva FF, Giustina A.
Endocrinol Metab Clin North Am. 2008 Mar;37(1):67-99, viii.
212. Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes.
Bossoni S, Mazziotti G, Gazzaruso C, Martinelli D, Orini S, Solerte SB, Romanelli G, Giustina A.
Age Ageing. 2008 Mar;37(2):222-5.
213. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.
De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A.
Pituitary. 2008;11(1):13-20.
214. Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency.
Mazziotti G, Bianchi A, Cimino V, Bonadonna S, Martini P, Fusco A, De Marinis L, Giustina A.
Pituitary. 2008;11(1):55-61.
215. Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary.
Carpinteri R, Patelli I, Casanueva FF, Giustina A.
Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5): 639-650
216. Pituitary gland: Medical therapy for acromegaly: can we predict response?
Giustina A, Porcelli T.
Nat Rev Endocrinol. 2009 Aug;5:425-7.
217. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Mancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, Vescovi PP, Giustina A.
Bone 2009; 45(4):784-8
218. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, de Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E.
Eur J Endocrinol. 2009 Aug;161:331-8.
219. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L.
J Clin Endocrinol Metab. 2009 Jun;94(6):2015-22.
220. Treatment with metformin is protective against limitations in instrumental activities of daily living in older subjects with type 2 diabetes mellitus.
Mazziotti G, Bossoni S, Orini S, Salimbeni P, Gazzaruso C, Solerte BS, Vescovi P, Romanelli G, Giustina A.
J Am Geriatr Soc. 2009 Mar;57(3):562-4.
221. Guidelines for acromegaly management: an update.
Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A; Acromegaly Consensus Group.
J Clin Endocrinol Metab. 2009 May;94(5):1509-17.

222. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.
Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A.
J Clin Endocrinol Metab. 2009 May;94(5):1500-8.
223. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.
Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A, De Marinis L.
Pituitary. 2009;12(3):196-9.
224. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Mazziotti G, Giustina A.
Pituitary 2010; 13: 60-67
225. Glucocorticoid-induced osteoporosis and parathyroid hormone.
Carpinteri R, Porcelli T, Mejia C, Patelli I, Bilezikian JP, Canalis E, Angeli A, Giustina A, Mazziotti G.
J Endocrinol Invest. 2010;33(7 Suppl):16-21.
226. Treatment of Cushing disease: overview and recent findings.
Mancini T, Porcelli T, Giustina A.
Ther Clin Risk Manag. 2010 Oct 21;6:505-16.
227. Drug-induced osteoporosis: mechanisms and clinical implications.
Mazziotti G, Canalis E, Giustina A.
Am J Med. 2010 Oct;123(10):877-84.
228. A consensus on criteria for cure of acromegaly.
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S; Acromegaly Consensus Group.
J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8.
229. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency.
Mazziotti G, Porcelli T, Bianchi A, Cimino V, Patelli I, Mejia C, Fusco A, Giampietro A, De Marinis L, Giustina A.
Eur J Endocrinol. 2010 Jul;163(1):15-20
230. Primary empty sella: Why and when to investigate hypothalamic-pituitary function.
Giustina A, Aimaretti G, Bondanelli M, Buzi F, Cannavò S, Cirillo S, Colao A, De Marinis L, Ferone D, Gasperi M, Grottoli S, Porcelli T, Ghigo E, degli Uberti E.
J Endocrinol Invest. 2010 May;33(5):343-6
231. Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density.
Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A.
Bone. 2010 Mar;46(3):747-51
232. Diabetes in Cushing syndrome: basic and clinical aspects.
Mazziotti G, Gazzaruso C, Giustina A.
Trends Endocrinol Metab. 2011 Dec;22(12):499-506.
233. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes.
Gazzaruso C, Coppola A, Montalcini T, Valenti C, Garzaniti A, Pelissero G, Salvucci F, Gallotti P, Pujia A, Falcone C, Solerte SB, Giustina A.
Endocrine. 2011 Oct;40(2):273-9.

234. Influence of diabetes mellitus on vertebral fractures in men with acromegaly.
Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L, Giustina A.
Endocrine. 2011 Aug;40(1):102-8.
235. Vertebral fractures in males with prolactinoma.
Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C, Mancini T, De Marinis L, Giustina A.
Endocrine. 2011 Jun;39(3):288-93.
236. Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group.
De Menis E, Giustina A, Colao A, Degli Uberti E, Ghigo E, Minuto F, Bogazzi F, Drigo R, Cattaneo A, Aimaretti G; COM.E.T.A. Italian Study Group.
J Endocrinol Invest. 2011 Jan;34(1):60-4. Erratum in: J Endocrinol Invest. 2011 Feb;34(2):169.
237. Erectile dysfunction and coronary artery disease in patients with diabetes.
Gazzaruso C, Coppola A, Giustina A.
Curr Diabetes Rev. 2011 Mar;7(2):143-7.
238. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas.
Mazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, Porcelli T, Vescovi PP, De Marinis L, Giustina A.
Pituitary. 2011 Dec;14(4):299-306.
239. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.
Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavò S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A.
Eur J Endocrinol. 2011 Mar;164(3):341-7
240. Current management practices for acromegaly: an international survey.
Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S.
Pituitary. 2011 Jun;14(2):125-33. doi: 10.1007/s11102-010-0269-9.
241. Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure.
Mazziotti G, Baracca M, Doga M, Porcelli T, Vescovi PP, Giustina A.
Eur J Endocrinol. 2012 Dec;167(6):865-72.
242. Growth hormone deficiency and cardiovascular risk: do we need additional markers?
Gola M, Giustina A.
Endocrine. 2012 Oct;42(2):240-2.
243. Keep an eye on nonfunctioning pituitary adenomas.
Giustina A.
Clin Endocrinol (Oxf). 2012 Nov;77(5):656-7.
244. Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function.
Tulipano G, Faggi L, Sibilia V, Giustina A.
Endocrine. 2012 Oct;42(2):292-8.

245. Meta-analysis on the effects of octreotide on tumor mass in acromegaly.
Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S.
PLoS One. 2012;7(5):e36411.
246. Type 2 diabetes mellitus is associated with faster degeneration of bioprosthetic valve: results from a propensity score-matched Italian multicenter study.
Lorusso R, Gelsomino S, Lucà F, De Cicco G, Billè G, Carella R, Villa E, Troise G, Viganò M, Banfi C, Gazzaruso C, Gagliardotto P, Menicanti L, Formica F, Paolini G, Benussi S, Alfieri O, Pastore M, Ferrarese S, Mariscalco G, Di Credico G, Leva C, Russo C, Cannata A, Trevisan R, Livi U, Scrofani R, Antona C, Sala A, Gensini GF, Maessen J, Giustina A.
Circulation. 2012 Jan 31;125(4):604-14.
247. High prevalence of radiological vertebral fractures in HIV-infected males.
Torti C, Mazziotti G, Soldini PA, Focà E, Maroldi R, Gotti D, Carosi G, Giustina A.
Endocrine. 2012 Jun;41(3):512-7. doi: 10.1007/s12020-011-9586-7
248. New understanding and treatments for osteoporosis.
Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A.
Endocrine. 2012 Feb;41(1):58-69. doi: 10.1007/s12020-011-9570-2.
249. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus.
Gazzaruso C, Coppola A, Montalcini T, Baffero E, Garzaniti A, Pelissero G, Collaviti S, Grugnetti A, Gallotti P, Pujia A, Solerte SB, Giustina A.
Endocrine. 2012 Feb;41(1):89-95.
250. Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients.
Gazzaruso C, Coppola A, Montalcini T, Valenti C, Pelissero G, Solerte SB, Salvucci F, Gallotti P, Pujia A, Garzaniti A, Giustina A.
Intern Emerg Med. 2012 Jun;7(3):257-66. doi: 10.1007/s11739-011-0527-5. Epub 2011 Feb 5.
251. Octreotide for acromegaly treatment: a reappraisal.
Giustina A, Karamouzis I, Patelli I, Mazziotti G.
Expert Opin Pharmacother. 2013 Dec;14(17):2433-47.
252. Commentary: Postsurgical monitoring of acromegaly.
Giustina A, Mazziotti G, Fontanella M.
Neurosurgery. 2013 Oct;73(4):E746-8.
253. Fat utilization and arterial hypertension in overweight/obese subjects.
Ferro Y, Gazzaruso C, Coppola A, Romeo S, Migliaccio V, Giustina A, Pujia A, Montalcini T.
J Transl Med. 2013 Jul 2;11:159.
254. Vertebral fractures in patients with acromegaly: a 3-year prospective study.
Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L, Giustina A.
J Clin Endocrinol Metab. 2013 Aug;98(8):3402-10
255. Percutaneous transluminal angioplasty for critical limb ischemia in very elderly diabetic patients.
Gazzaruso C, Coppola A, Collaviti S, Saluzzo CM, Furlani F, Gallotti P, Clerissi J, Solerte BS, Giustina A.
Aging Clin Exp Res. 2013 May;25(2):225-8.
256. Primary headache and silent myocardial ischemia in patients with coronary artery disease.

- Falcone C, Bozzini S, Gazzaruso C, Calcagnino M, Ghiotto N, Falcone R, Coppola A, Giustina A, Pelissero G.
Cardiology. 2013;125(3):133-8.
257. Effect of different diabetes mellitus treatments on functional decline and death in elderly adults with diabetes mellitus.
 Gazzaruso C, Coppola A, Luppi C, Giustina A, Solerte SB.
J Am Geriatr Soc. 2013 Apr;61(4):666-7
258. Should we abandon statins in the prevention of bone fractures?
 Esposito K, Capuano A, Sportiello L, Giustina A, Giugliano D.
Endocrine. 2013 Oct;44(2):326-33
259. Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index.
 Gazzaruso C, Coppola A, Falcone C, Luppi C, Montalcini T, Baffero E, Gallotti P, Pujia A, Solerte SB, Pelissero G, Giustina A
Diabetes Care 2013 June; 36: 1720-5
260. Glucocorticoids and the regulation of growth hormone secretion.
 Mazziotti G, Giustina A.
Nat Rev Endocrinol. 2013 May;9(5):265-76.
261. Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells.
 Tulipano G, Faggi L, Losa M, Mortini P, Spinello M, Sibilìa V, Pagani F, Cocchi D, Giustina A.
Mol Cell Endocrinol. 2013 Jan 30;365(2):197-206.
262. Effects of recombinant follicle-stimulating hormone on bone turnover markers in infertile women undergoing in vitro fertilization procedure.
 Omodei U, Mazziotti G, Donarini G, Gola M, Guella V, Pagani F, Bugari G, Porcelli T, Giustina A.
J Clin Endocrinol Metab. 2013 Jan;98(1):330-6.
263. A consensus on the diagnosis and treatment of acromegaly complications.
 Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A.
Pituitary. 2013 Sep;16(3):294-302.
264. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline.
 Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo' S, De Marinis L, De Menis E, Grottoli S, Pivonello R.
J Endocrinol Invest. 2014 Oct;37(10):1017-30.
265. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
 Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A.
Expert Opin Investig Drugs. 2014 Dec;23(12):1619-35.
266. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.
 Porcelli T, Gotti D, Cristiano A, Maffezzoni F, Mazziotti G, Focà E, Castelli F, Giustina A, Quiros-Roldan E.
Osteoporos Int. 2014 Sep;25(9):2263-9.
267. Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs.

- Mazziotti G, Maffezzoni F, Doga M, Hofbauer LC, Adler RA, Giustina A. *Bone*. 2014 Oct;67:175-80.
268. Molecular imaging in acromegaly: should clinicians look carefully at developments in the field?
Giustina A, Mazziotti G, Giubbini R. *Nucl Med Commun*. 2014 Sep;35(9):897-9.
269. GH receptor isoforms and skeletal fragility in acromegaly.
Mormando M, Nasto LA, Bianchi A, Mazziotti G, Giampietro A, Pola E, Pontecorvi A, Giustina A, De Marinis L. *Eur J Endocrinol*. 2014 Aug;171(2):237-45
270. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism.
Mazziotti G, Mormando M, Cristiano A, Bianchi A, Porcelli T, Giampietro A, Maffezzoni F, Serra V, De Marinis L, Giustina A. *Eur J Endocrinol*. 2014 Jun;170(6):893-9
271. Elevated intraocular pressure in patients with acromegaly.
Quaranta L, Riva I, Mazziotti G, Porcelli T, Floriani I, Katsanos A, Giustina A, Konstas AG. *Graefes Arch Clin Exp Ophthalmol*. 2014 Jul;252(7):1133-9
272. Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect.
Giustina A, Mazziotti G. *Endocrine*. 2014 Nov;47(2):354-6
273. Expert consensus document: A consensus on the medical treatment of acromegaly.
Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S; Acromegaly Consensus Group. *Nat Rev Endocrinol*. 2014 Apr;10(4):243-8.
274. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.
Kamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P. *Endocr Rev*. 2014 Apr;35(2):234-81.
275. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?
Scillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R, Giustina A, Colao A; ABC Group. *Osteoporos Int*. 2014 Feb;25(2):441-6.
276. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH—an update.
Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. *J Clin Endocrinol Metab*. 2014 Jan;99(1):18-29.
277. Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in vitro.
Tulipano G, Faggi L, Cacciamali A, Spinello M, Cocchi D, Giustina A. *Pituitary*. 2014 Jun;17(3):203-9.

278. Maffezzoni F, Porcelli T, Karamouzis I, et al. Osteoporosis in Human Immunodeficiency Virus Patients - An Emerging Clinical Concern. *Eur Endocrinol*. 2014;10(1):79-83. doi:10.17925/EE.2014.10.01.79
279. Parathyroid hormone pulsatility: physiological and clinical aspects. Chiavistelli S, Giustina A, Mazziotti G. *Bone Res*. 2015 Jan 27;3:14049
280. Growth hormone replacement therapy and fracture risk. Giustina A, Mazziotti G. *Lancet Diabetes Endocrinol*. 2015 May;3(5):307-8.
281. Cortisol and the muscle-bone axis: response to comments by Molino et al. Scillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R, Giustina A, Colao A; ABC 2011. *Osteoporos Int*. 2015 May;26(5):1661-2.
282. Pituitary diseases and bone. Mazziotti G, Chiavistelli S, Giustina A. *Endocrinol Metab Clin North Am*. 2015 Mar;44(1):171-80.
283. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C. *J Clin Endocrinol Metab*. 2015 Apr;100(4):1699-708.
284. Growth hormone deficiency in treated acromegaly. Mazziotti G, Marzullo P, Doga M, Aimaretti G, Giustina A. *Trends Endocrinol Metab*. 2015 Jan;26(1):11-21.
285. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I, Giustina A. *J Clin Endocrinol Metab*. 2015 Feb;100(2):384-94
286. Optimal use of pegvisomant in acromegaly: are we getting there? Giustina A. *Endocrine*. 2015 Feb;48(1):3-8.
287. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells. Tulipano G, Faggi L, Cacciamali A, Spinello M, Cocchi D, Giustina A. *J Neuroendocrinol*. 2015 Jan;27(1):20-32.
288. Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor? Giustina A, Berardelli R, Gazzaruso C, Mazziotti G. *Acta Diabetol*. 2015 Jun;52(3):433-43.
289. Current and future medical treatments for patients with acromegaly. Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A. *Expert Opin Pharmacother*. 2016 Jun 28:1-12.
290. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Frara S, Maffezzoni F, Mazziotti G, Giustina A. *Trends Endocrinol Metab*. 2016 Jul;27(7):470-83.

291. Skeletal Fragility in Endogenous Hypercortisolism.
Mazziotti G, Delgado A, Maffezzoni F, Formenti A, Giustina A.
Front Horm Res. 2016;46:66-73
292. The Modern Criteria for Medical Management of Acromegaly.
Frara S, Maffezzoni F, Mazziotti G, Giustina A.
Prog Mol Biol Transl Sci. 2016;138:63-83.
293. Treatment of hypothyroidism: all that glitters is gold?
Formenti AM, Mazziotti G, Giubbini R, Giustina A.
Endocrine. 2016 Jun;52(3):411-3.
294. Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy?
Mazziotti G, Maffezzoni F, Giustina A.
Endocrine. 2016 May;52(2):183-6
295. High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome.
Mazziotti G, Dordoni C, Doga M, Galderisi F, Venturini M, Calzavara-Pinton P, Maroldi R, Giustina A, Colombi M.
Bone. 2016 Mar;84:88-92.
296. The role of patient education in the prevention and management of type 2 diabetes: an overview.
Coppola A, Sasso L, Bagnasco A, Giustina A, Gazzaruso C.
Endocrine. 2016 Jul;53(1):18-27
297. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.
Mazziotti G, Doga M, Frara S, Maffezzoni F, Porcelli T, Cerri L, Maroldi R, Giustina A.
Endocrine. 2016 Apr;52(1):103-10.
298. SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study.
Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S; SAGIT Investigator Group.
Pituitary. 2016 Feb;19(1):39-49.
299. Bone and Joint Disorders in Acromegaly.
Claessen KM, Mazziotti G, Biermasz NR, Giustina A.
Neuroendocrinology. 2016; 103: 86-95
300. New oral anticoagulants and pituitary apoplexy.
Doglietto F, Costi E, Villaret AB, Mardighian D, Fontanella MM, Giustina A.
Pituitary. 2016 Apr;19(2):232-4.
301. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone deficient patients
Mormando M, Chiloiro S, Bianchi A, Giampietro A, Angelini F, Tartaglione L, Nasto L, Milardi D, Formenti AM, Giustina A, De Marinis L
Clin Endocrinol 2016 Nov 85: 717-724
302. High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures.
Maffezzoni F, Maddalo M, Frara S, Mezzone M, Zorza I, Baruffaldi F, Doglietto F, Mazziotti G, Maroldi R, Giustina A.
Endocrine. 2016 Nov;54(2):532

303. New medical therapies of acromegaly.
Maffezzoni F, Frara S, Doga M, Mazziotti G, Giustina A.
Growth Horm IGF Res. 2016 Oct – Dec;30-31:58-63
304. Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.
Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A.
Endocrine. 2016 Dec;54(3):603-611.
305. Erectile dysfunction as a predictor of asymptomatic coronary artery disease in elderly men with type 2 diabetes.
Gazzaruso C, Coppola A, Pujia A, Falcone C, Collaviti S, Fodaro M, Gallotti P, Solerte SB, Giustina A, Pelissero G, Luzi L, Montalcini T.
J Geriatr Cardiol. 2016 Sep;13(6):552-6.
306. [Acromegaly: reducing diagnostic delay].
Giustina A.
Recenti Prog Med. 2016 Aug;107(8):450-1.
307. Casanueva FF, Barkan AL, Buchfelder M, et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement [published correction appears in *Pituitary.* 2018 Sep 20;:]. *Pituitary.* 2017;20(5):489-498. doi:10.1007/s11102-017-0838-2
308. Giustina A, Arnaldi G, Bogazzi F, et al. Pegvisomant in acromegaly: an update [published correction appears in *J Endocrinol Invest.* 2017 Dec 28;:]. *J Endocrinol Invest.* 2017;40(6):577-589. doi:10.1007/s40618-017-0614-1
309. Mazziotti G, Maffezzoni F, Frara S, Giustina A. Acromegalic osteopathy. *Pituitary.* 2017;20(1):63-69. doi:10.1007/s11102-016-0758
310. Mazziotti G, Formenti AM, Frara S, Maffezzoni F, Doga M, Giustina A. Diabetes in Cushing Disease. *Curr Diab Rep.* 2017;17(5):32. doi:10.1007/s11892-017-0860-9
311. Giustina A, Mazziotti G, Cannavò S, et al. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. *J Clin Endocrinol Metab.* 2017;102(7):2454-2464. doi:10.1210/jc.2017-00142
312. Formenti AM, Maffezzoni F, Doga M, Mazziotti G, Giustina A. Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. *Best Pract Res Clin Endocrinol Metab.* 2017;31(1):79-90. doi:10.1016/j.beem.2017.03.002
313. Mazziotti G, Formenti AM, Frara S, et al. MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. *Eur J Endocrinol.* 2017;177(5):R231-R248. doi:10.1530/EJE-17-0154
314. Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. *Expert Opin Pharmacother.* 2017;18(16):1679-1689. doi:10.1080/14656566.2017.1391217
315. Pedersini R, Monteverdi S, Mazziotti G, et al. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. *Bone.* 2017;97:147-152. doi:10.1016/j.bone.2017.01.013
316. Mazziotti G, Frara S, Giustina A. Pituitary Diseases and Bone. *Endocr Rev.* 2018 Aug 1;39(4):440-488. doi: 10.1210/er.2018-00005. PMID: 29684108.
317. Tulipano G, Faggi L, Schulz S, Spinello M, Giustina A. Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells. *Endocrine.* 2017;57(1):179-182. doi:10.1007/s12020-017-1235-3

318. Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. *Nat Rev Endocrinol*. 2018;14(9):552-561. doi:10.1038/s41574-018-0058-5
319. Pascale A, Marchesi N, Marelli C, et al. Microbiota and metabolic diseases. *Endocrine*. 2018;61(3):357-371. doi:10.1007/s12020-018-1605-5
320. Tecilazich F, Formenti AM, Frara S, Giubbini R, Giustina A. Treatment of hypoparathyroidism. *Best Pract Res Clin Endocrinol Metab*. 2018;32(6):955-964. doi:10.1016/j.beem.2018.12.002
321. Sempos CT, Heijboer AC, Bikle DD, et al. Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. *Br J Clin Pharmacol*. 2018;84(10):2194-2207. doi:10.1111/bcp.13652
322. Ebeling PR, Adler RA, Jones G, et al. MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D. *Eur J Endocrinol*. 2018;179(5):R239-R259. Published 2018 Oct 12. doi:10.1530/EJE-18-0151
323. Giustina A. Fabula (non) acta est....*Endocrine*. *Endocrine*. 2018;62(3):503-505. doi:10.1007/s12020-018-1790-2
324. Mazziotti G, Formenti AM, Panarotto MB, et al. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. *Endocrine*. 2018;59(1):90-101. doi:10.1007/s12020-017-1455-6
325. Cipriani C, Pepe J, Bertoldo F, et al. The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. *J Endocrinol Invest*. 2018;41(4):431-438. doi:10.1007/s40618-017-0761-4
326. Frara S, Chiloiro S, Porcelli T, et al. Bone safety of dual-release hydrocortisone in patients with hypopituitarism. *Endocrine*. 2018;60(3):528-531. doi:10.1007/s12020-017-1512-1
327. Ragonese M, Grottoli S, Maffei P, et al. How to improve effectiveness of pegvisomant treatment in acromegalic patients. *J Endocrinol Invest*. 2018;41(5):575-581. doi:10.1007/s40618-017-0773-0
328. Mazziotti G, Formenti AM, Frara S, et al. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma. *J Clin Endocrinol Metab*. 2018;103(3):956-964. doi:10.1210/jc.2017-01986
329. Frara S, Losa M, Doga M, et al. High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma [published correction appears in *J Endocr Soc*. 2018 Dec 28;3(2):358]. *J Endocr Soc*. 2018;2(9):1089-1099. Published 2018 Jul 27. doi:10.1210/js.2018-00091
330. Chiloiro S, Mazziotti G, Giampietro A, et al. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly [published correction appears in *Pituitary*. 2018 Feb 23;:]. *Pituitary*. 2018;21(3):302-308. doi:10.1007/s11102-018-0873-7
331. Faggi L, Giustina A, Tulipano G. Effects of metformin on cell growth and AMPK activity in pituitary adenoma cell cultures, focusing on the interaction with adenylyl cyclase activating signals. *Mol Cell Endocrinol*. 2018;470:60-74. doi:10.1016/j.mce.2017.09.030
332. Chiloiro S, Mormando M, Bianchi A, et al. Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. *Endocrine*. 2018;59(2):449-453. doi:10.1007/s12020-017-1391-5
333. Albano D, Bertagna F, Bonacina M, et al. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. *Eur J Endocrinol*. 2018;179(3):143-151. doi:10.1530/EJE-18-0253

334. Colao A, Grasso LFS, Giustina A, et al. Acromegaly [published correction appears in *Nat Rev Dis Primers*. 2019 Oct 21;5(1):72]. *Nat Rev Dis Primers*. 2019;5(1):20. Published 2019 Mar 21. doi:10.1038/s41572-019-0071-6
335. Chiloiro S, Capoluongo ED, Tartaglione T, et al. The Changing Clinical Spectrum of Hypophysitis. *Trends Endocrinol Metab*. 2019;30(9):590-602. doi:10.1016/j.tem.2019.06.004
336. Giustina A, Adler RA, Binkley N, et al. Controversies in Vitamin D: Summary Statement From an International Conference. *J Clin Endocrinol Metab*. 2019;104(2):234-240. doi:10.1210/jc.2018-01414
337. Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. *Endocr Rev*. 2019;40(4):1109-1151. doi:10.1210/er.2018-00126
338. Formenti AM, Tecilazich F, Giubbini R, Giustina A. Risk of vertebral fractures in hypoparathyroidism. *Rev Endocr Metab Disord*. 2019;20(3):295-302. doi:10.1007/s11154-019-09507-x
339. Ho KKY, Fleseriu M, Wass J, et al. A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement. *Pituitary*. 2019;22(6):569-573. doi:10.1007/s11102-019-00988-2
340. Formenti AM, Doga M, Frara S, et al. Skeletal fragility: an emerging complication of Ehlers-Danlos syndrome. *Endocrine*. 2019;63(2):225-230. doi:10.1007/s12020-018-1822-y
341. Giustina A, Bronstein MD, Chanson P, et al. Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. *Pituitary*. 2019;22(5):476-487. doi:10.1007/s11102-019-00977-5
342. Pedersini R, Amoroso V, Maffezzoni F, et al. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy. *JAMA Netw Open*. 2019;2(9):e1911080. Published 2019 Sep 4. doi:10.1001/jamanetworkopen.2019.11080
343. Formenti AM, Tecilazich F, Frara S, Giubbini R, De Luca H, Giustina A. Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism. *Endocrine*. 2019;66(3):699-700. doi:10.1007/s12020-019-02105-6
344. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. *Endocrine*. 2020;68(1):2-5. doi:10.1007/s12020-020-02294-5
345. Castellana M, Conte E, Cignarelli A, et al. Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. *Rev Endocr Metab Disord*. 2020;21(1):5-16. doi:10.1007/s11154-019-09514-y
346. Giustina A, Barkan A, Beckers A, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. *J Clin Endocrinol Metab*. 2020;105(4):dgz096. doi:10.1210/clinem/dgz096
347. di Filippo L, Doga M, Resmini E, Giustina A. Hyperprolactinemia and bone. *Pituitary*. 2020;23(3):314-321. doi:10.1007/s11102-020-01041-3
348. Giustina A, Adler RA, Binkley N, et al. Consensus statement from 2nd International Conference on Controversies in Vitamin D. *Rev Endocr Metab Disord*. 2020;21(1):89-116. doi:10.1007/s11154-019-09532-w
349. Ho KKY, Fleseriu M, Wass J, et al. The tale in evolution: clarity, consistency and consultation, not contradiction and confusion [published online ahead of print, 2020 Jan 7]. *Pituitary*. 2020;10.1007/s11102-019-01027-w. doi:10.1007/s11102-019-01027-w

350. Chiloiro S, Giampietro A, Frara S, et al. Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. *J Clin Endocrinol Metab.* 2020;105(3):dgz054. doi:10.1210/clinem/dgz054
351. Giustina A. Acromegaly and Vertebral Fractures: Facts and Questions. *Trends Endocrinol Metab.* 2020;31(4):274-275. doi:10.1016/j.tem.2020.01.011
352. Tulipano G, Giustina A. Effects of octreotide on autophagy markers and cell viability markers related to metabolic activity in rat pituitary tumor cells. *Pituitary.* 2020;23(3):223-231. doi:10.1007/s11102-020-01028-0
353. Bossoni S, Chiesa L, Giustina A. Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection [published online ahead of print, 2020 Apr 28]. *Endocrine.* 2020;1-2. doi:10.1007/s12020-020-02326-0
354. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N, Accili D, Binkley N, Landry DW, Giustina A. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. *Eur J Endocrinol.* 2020 Nov;183(5):R133-R147. doi: 10.1530/EJE-20-0665. PMID: 32755992.
355. Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. *Rev Endocr Metab Disord.* 2020 Dec;21(4):495-507. doi: 10.1007/s11154-020-09569-2. PMID: 32643004; PMCID: PMC7343578.
356. Donini LM, Busetto L, Bauer JM, Bischoff S, Boirie Y, Cederholm T, Cruz-Jentoft AJ, Dicker D, Frühbeck G, Giustina A, Gonzalez MC, Han HS, Heymsfield SB, Higashiguchi T, Laviano A, Lenzi A, Parrinello E, Poggiogalle E, Prado CM, Rodriguez JS, Rolland Y, Santini F, Siervo M, Tecilazich F, Vettor R, Yu J, Zamboni M, Barazzoni R. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. *Clin Nutr.* 2020 Aug;39(8):2368-2388. doi: 10.1016/j.clnu.2019.11.024. Epub 2019 Nov 27. PMID: 31813698.
357. Di Filippo L, Formenti AM, Rovere-Querini P, Carlucci M, Conte C, Ciceri F, Zangrillo A, Giustina A. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. *Endocrine.* 2020 Jun;68(3):475-478. doi: 10.1007/s12020-020-02383-5. Epub 2020 Jun 12. PMID: 32533508; PMCID: PMC7292572.
358. Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S. Multidisciplinary management of acromegaly: A consensus. *Rev Endocr Metab Disord.* 2020 Dec;21(4):667-678. doi: 10.1007/s11154-020-09588-z. Epub 2020 Sep 10. PMID: 32914330.
359. Mortini P, Nocera G, Roncelli F, Losa M, Formenti AM, Giustina A. The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective. *Rev Endocr Metab Disord.* 2020 Dec;21(4):527-536. doi: 10.1007/s11154-020-09564-7. PMID: 32488741.
360. Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF. Pituitary Tumors Centers of Excellence. *Endocrinol Metab Clin North Am.* 2020 Sep;49(3):553-564. doi: 10.1016/j.ecl.2020.05.010. Epub 2020 Jul 15. PMID: 32741488.
361. Brandi ML, Giustina A. Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. *Trends Endocrinol Metab.* 2020 Sep 24:S1043-2760(20)30181-8. doi: 10.1016/j.tem.2020.09.003. Epub ahead of print. PMID: 33082024; PMCID: PMC7513816.

362. Petersenn S, Giustina A. Diagnosis and management of prolactinomas: current challenges. *Pituitary*. 2020 Feb;23(1):1-2. doi: 10.1007/s11102-019-01025-y. PMID: 31900881.
363. Tecilazich F, Formenti AM, Giustina A. Role of vitamin D in diabetic retinopathy: Pathophysiological and clinical aspects. *Rev Endocr Metab Disord*. 2020 Oct 7:1–13. doi: 10.1007/s11154-020-09575-4. Epub ahead of print. PMID: 33026598; PMCID: PMC7538371.
364. Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. *J Clin Endocrinol Metab*. 2020 Oct 1;105(10):dgaa526. doi: 10.1210/clinem/dgaa526. PMID: 32882036; PMCID: PMC7470473.
365. di Filippo L, Formenti AM, Giustina A. Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19. *Endocrine*. 2020 Oct 22:1–2. doi: 10.1007/s12020-020-02525-9. Epub ahead of print. PMID: 33094473; PMCID: PMC7580813.
366. Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S. A Pituitary Society update to acromegaly management guidelines. *Pituitary*. 2020 Oct 20. doi: 10.1007/s11102-020-01091-7. Epub ahead of print. PMID: 33079318.
367. Formenti AM, Pedone E, di Filippo L, Ulivieri FM, Giustina A. Are women with osteoporosis treated with denosumab at risk of severe COVID-19? *Endocrine*. 2020 Nov;70(2):203-205. doi: 10.1007/s12020-020-02500-4. Epub 2020 Sep 20. PMID: 32951069; PMCID: PMC7502215.
368. Gazzaruso C, Gallotti P, Pujia A, Montalcini T, Giustina A, Coppola A. Predictors of healing, ulcer recurrence and persistence, amputation and mortality in type 2 diabetic patients with diabetic foot: a 10-year retrospective cohort study. *Endocrine*. 2020 Jul 25. doi: 10.1007/s12020-020-02431-0. Epub ahead of print. PMID: 32712853.
369. Tulipano G, Paghera S, Missale C, Giustina A. Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors. *Endocrine*. 2020 Sep;69(3):604-614. doi: 10.1007/s12020-020-02373-7. Epub 2020 Jun 16. PMID: 32557328.
370. Giustina A, Bouillon R, Binkley N, Sempos C, Adler RA, Bollerslev J, Dawson-Hughes B, Ebeling PR, Feldman D, Heijboer A, Jones G, Kovacs CS, Lazaretti-Castro M, Lips P, Marcocci C, Minisola S, Napoli N, Rizzoli R, Scragg R, White JH, Formenti AM, Bilezikian JP. Controversies in Vitamin D: A Statement From the Third International Conference. *JBMR Plus*. 2020 Nov 10;4(12):e10417. doi: 10.1002/jbm4.10417. PMID: 33354643; PMCID: PMC7745884.
371. Parodi MB, Arrigo A, Rajabian F, Tecilazich F, Giustina A, Bandello F, Jampol LM. Paracentral acute middle maculopathy in central retinal vein occlusion complicating AL-amyloidosis. *Retin Cases Brief Rep*. 2020 Nov 6. doi: 10.1097/ICB.0000000000001061. Epub ahead of print. PMID: 33181801.
372. di Filippo L, Formenti AM, Doga M, Frara S, Rovere-Querini P, Bosi E, Carlucci M, Giustina A. Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. *Endocrine*. 2020 Nov 9:1–5. doi: 10.1007/s12020-020-02541-9. Epub ahead of print. PMID: 33165763; PMCID: PMC7649576.

373. S, Monteverdi, R. Pedersini, F. Gallo, F. Maffezzoni, A. Dalla Volta, P. Di Mauro, A. Turla, L. Vassalli, M. Ardine, A. M. Formenti, E. L. Simoncini, A. Giustina, R. Maroldi, V. Amoroso, A. Berruti The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy *JBMR Plus* 2020 <https://doi.org/10.1002/jbm4.10440>
374. Giustina A, Legg E, Cesana BM, Frara S, Mortini P, Fleseriu M. Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. *Endocrine*. 2021 Jan 7:1–8. doi: 10.1007/s12020-020-02565-1. Epub ahead of print. PMID: 33415577; PMCID: PMC7790473.
375. Hutchings N, Babalyan V, Baghdasaryan S, Qefoyan M, Sargsyants N, Aghajanova E, Martirosyan A, Harutyunyan R, Lesnyak O, Formenti AM, Giustina A, Bilezikian JP. Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. *Endocrine*. 2021 Jan 16:1–3. doi: 10.1007/s12020-020-02597-7. Epub ahead of print. PMID: 33452994; PMCID: PMC7811339.
376. di Filippo L, Formenti AM, Doga M, Pedone E, Rovere-Querini P, Giustina A. Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes. *J Clin Endocrinol Metab*. 2021 Jan 23;106(2):e602-e614. doi: 10.1210/clinem/dgaa738. PMID: 33159451; PMCID: PMC7797741.
377. Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Liverana L, Gessi M, Carmelo A, Rindi G, Giustina A, Fleseriu M, Pontecorvi A, De Marinis L, Bianchi A. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. *Eur J Endocrinol*. 2021 Feb;184(2):217-229. doi: 10.1530/EJE-20-0767. PMID: 33136550.
378. Formenti AM, Dalla Volta A, di Filippo L, Berruti A, Giustina A. Effects of Medical Treatment of Prostate Cancer on Bone Health. *Trends Endocrinol Metab*. 2021 Jan 25:S1043-2760(20)30253-8. doi: 10.1016/j.tem.2020.12.004. Epub ahead of print. PMID: 33509658.
379. Giustina A. Hypovitaminosis D and the endocrine phenotype of COVID-19. *Endocrine*. 2021 Mar 18. doi: 10.1007/s12020-021-02671-8. Epub ahead of print. PMID: 33738708.
380. di Filippo L, Doga M, Frara S, Giustina A. Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications. *Rev Endocr Metab Disord*. 2021 Apr 13:1–10. doi: 10.1007/s11154-021-09655-z. Epub ahead of print. PMID: 33846867; PMCID: PMC8041474.
381. Tulipano G, Giustina A. Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly. *Rev Endocr Metab Disord*. 2021 Apr 5. doi: 10.1007/s11154-021-09649-x. Epub ahead of print. PMID: 33821422.


382. Frara S, Allora A, di Filippo L, Formenti AM, Loli P, Polizzi E, Tradati D, Olivieri FM, Giustina A. Osteopathy in mild adrenal Cushing's syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab. 2021 Mar 10:101515. doi: 10.1016/j.beem.2021.101515. Epub ahead of print. PMID: 33795196.

1.

H indx 75 (Google Scholar)
Total Citations 26.300 (Google Scholar)
I10-index 285 (Google Scholar)

Milan, 11/10/2022

Prof. Andrea Giustina

A handwritten signature in blue ink that reads "Andrea Giustina". The signature is written in a cursive, flowing style.